相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial
Timo Vesikari et al.
LANCET RESPIRATORY MEDICINE (2018)
Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine
Eun-Ju Ko et al.
JOURNAL OF IMMUNOLOGY (2017)
Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells
Rossella Cioncada et al.
PLOS ONE (2017)
Towards an evidence based approach for the development of adjuvanted vaccines
Derek T. O'Hagan et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Safety of vaccination against influenza A (H1N1) during pregnancy in the Netherlands: results on pregnancy outcomes and infant's health: cross-sectional linkage study
N. van der Maas et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2016)
Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells
Eun-Ju Ko et al.
JOURNAL OF VIROLOGY (2016)
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition
Monica Vaccari et al.
NATURE MEDICINE (2016)
Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood
Helder I. Nakaya et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial
David I. Bernstein et al.
VACCINE (2016)
Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines
Ji Yun Noh et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction
Natasha Dubois Cauwelaert et al.
PLOS ONE (2016)
Different human vaccine adjuvants promote distinct antigenin-dependent immunological signatures tailored to different pathogens
Niels Peter H. Knudsen et al.
SCIENTIFIC REPORTS (2016)
MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life
Beatris Mastelic Gavillet et al.
JOURNAL OF IMMUNOLOGY (2015)
A/H1N1 pandemic influenza vaccination: A retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy
Massimo Fabiani et al.
VACCINE (2015)
Influenza vaccination in children primed with MF59®-adjuvanted or non-adjuvanted seasonal influenza vaccine
Timo Vesikari et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children
Markus Knuf et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
MF59-and Al(OH)3-adjuvanted Staphylococcus aureus (4C-staph) vaccines induce sustained protective humoral and cellular immune responses, with a critical role for effector CD4 T cells at low antibody titers
Elisabetta Monaci et al.
FRONTIERS IN IMMUNOLOGY (2015)
Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 Adjuvant A Randomized Clinical Trial
Robert B. Belshe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination
Keith S. Reisinger et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
The history of MF59 (R) adjuvant: a phoenix that arose from the ashes
Derek T. O'Hagan et al.
EXPERT REVIEW OF VACCINES (2013)
Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults
Paolo Palma et al.
BIOLOGICALS (2012)
MF59 and Pam3CSK4 Boost Adaptive Responses to Influenza Subunit Vaccine through an IFN Type I-Independent Mechanism of Action
Elena Caproni et al.
JOURNAL OF IMMUNOLOGY (2012)
Synchronization of Dendritic Cell Activation and Antigen Exposure Is Required for the Induction of Th1/Th17 Responses
Arun T. Kamath et al.
JOURNAL OF IMMUNOLOGY (2012)
Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans
Tom M. Wilkinson et al.
NATURE MEDICINE (2012)
Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants
Rachel P. J. Lai et al.
PLOS ONE (2012)
Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein
Antu K. Dey et al.
VACCINE (2012)
The mechanism of action of MF59 - An innately attractive adjuvant formulation
D. T. O'Hagan et al.
VACCINE (2012)
MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine
Manmohan Singh et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
MF59 adjuvant: the best insurance against influenza strain diversity
Derek T. O'Hagan et al.
EXPERT REVIEW OF VACCINES (2011)
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88
Anja Seubert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59
Ali H. Ellebedy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients
Massimiliano Fabbiani et al.
VACCINE (2011)
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes
Samuele Calabro et al.
VACCINE (2011)
Immune mechanisms of protection: can adjuvants rise to the challenge?
Amy S. McKee et al.
BMC BIOLOGY (2010)
AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
Arnaud M. Didierlaurent et al.
JOURNAL OF IMMUNOLOGY (2009)
MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)
Barbara C. Baudner et al.
PHARMACEUTICAL RESEARCH (2009)
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine
Grazia Galli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment
George S. Hui et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2008)
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells
Anja Seubert et al.
JOURNAL OF IMMUNOLOGY (2008)
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults
David I. Bernstein et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice
Andreas Wack et al.
VACCINE (2008)
The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine
George Hui et al.
VACCINE (2007)
A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens
M Singh et al.
VACCINE (2006)
分享论文
